We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Molecular Diagnostics Optimized for Breast Cancer Tissue Samples

By LabMedica International staff writers
Posted on 16 Jan 2014
A prognostic 70-gene profile assay for early-stage breast cancer has been available for fresh tissue, and improvements in ribonucleic acid (RNA) processing have enabled microarray diagnostics for formalin-fixed, paraffin-embedded (FFPE) tissue.

The test is based on accurate measurement of gene expression by microarray analysis and has been developed and validated for fresh and fresh-frozen tumor tissue to guarantee high-quality RNA for the analysis. More...
Gene expression analysis using FFPE tissue has long been challenging, because of nonstandardized fixation protocols and because of unreliable retrieval of high-quality RNA from FFPE material due to fragmentation of RNA and cross-linking as a result of formalin fixation.

Scientists at the University of Turin (Italy) and colleagues from other organizations, optimized the assay on 157 FFPE samples, and the assay was established using 125 matched FFPE and fresh tissue samples. Validation of the MammaPrint-FFPE assay (Agendia; Irvine, CA, USA), was compared with the company’s MammaPrint-fresh assay and was performed on an independent series of matched tissue for 211 samples from five hospitals.

The MammaPrint assay using FFPE analyte demonstrated an overall equivalence of 91.5% between the 211 independent matched FFPE and fresh tumor samples. Precision was 97.3%, and repeatability was 97.8%, with highly reproducible results between replicate samples of the same tumor and between two laboratories. Precision and repeatability of the FFPE assay were assessed on a set of four diagnostic samples that were processed and analyzed in duplicate for 20 consecutive days. MammaPrint showed very stable results on FFPE, with a very high relative stability for precision.

The authors concluded that the MammaPrint test can be used on core and surgical sections from FFPE tissue as an alternative to fresh tissue. The MammaPrint-FFPE assay has excellent reproducibility, precision, and repeatability, with performance closely similar to that of MammaPrint-fresh. The study was published on December 28, 2013, in the Journal of Molecular Diagnostics.

Related Links:

University of Turin
Agendia



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.